Table 1.
Baseline characteristics at start and reasons for later discontinuation of first TNF inhibitor.
Table 2.
Baseline characteristics at start of first TNF inhibitor of patients retained in the drug retention analysis.
Fig 1.
Kaplan-Meier curves showing drug survival of the first TNFi, stratified by the type of TNFi used.
A. Treatment initiation during the whole observation time in SCQM. B-D. Stratitication by the number of TNFi available as treatment options at the time-point of treatment initiation. B. ETA and IFX in treatment initiation 2004–2005. C. ADA, ETA and IFX in treatment initiations 2006–2009. D. ADA, ETA, GOL and IFX in treatment initiations after 2009. ADA = adalimumab, ETA = etanercept, GOL = golimumab, IFX = infliximab.
Fig 2.
Multivariable adjusted Cox regression models for drug survival (A) and drug survival up to dose escalation (B) in axSpA patients treated with a first TNFi. ETA and the period after 2009 are used as references in this models. HRs >1 indicate increased hazard for discontinuation. ADA = adalimumab, AS = ankylosing spondylitis, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, BASFI = Bath Ankylosing Spondylitis Functional Index, BMI = body mass index, CI = confidence interval, CRP = C-reactive protein, csDMARD = conventional synthetic disease-modifying anti-rheumatic drug, ETA = etanercept, GOL = golimumab, HLA-B27 = Human Leucocyte Antigen B27, HR = hazard ratio, IFX = infliximab, nr-axSpA = nonradiographic axial spondyloarthritis, TNFi = Tumor Necrosis Factor inhibitor.
Table 3.
Multivariable adjusted Cox regression models with complete case data.
Table 4.
Comparison of drug survival as well as drug survival up to dose escalation between different anti-TNF agents, stratified by the period of treatment initiation, in respective multiple adjusted cox regression models.
Fig 3.
Kaplan-Meier curve showing drug maintenance of the first TNFi up to dose escalation, stratified by the type of TNFi used.
ADA = adalimumab, ETA = etanercept, GOL = golimumab, IFX = infliximab.